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ORIGINAL ARTICLE
Surfing, self-medicating and safety: buying
non-prescription and complementary medicines via the
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Objective: To examine whether the sale of medicines via the internet supports their safe and appropri-
ate use.
Design: e-Pharmacy websites were identified using key words and a metasearch engine and the qual-
ity of information published on these websites was surveyed using the DISCERN tool. A case scenario
and internet pharmacy practice standards were also used to evaluate the quality of care delivered.
Setting and participants: Between July and September 2001 104 websites were surveyed and 27
sent either Sudafed (pseudoephedrine HCl), St John’s wort products, or both to a residential address in
Melbourne, Australia.
Main outcome measures: Quality of health information (DISCERN ratings), information exchanged
between e-pharmacy staff and consumers, and product and delivery costs.
Results: Of 104 e-pharmacies from at least 13 different countries, 63 websites provided some health
information but overall the quality of the information was poor. Only three website operators provided
adequate advice to consumers to avoid a potential drug interaction. The costs for a daily dose of pseu-
doephedrine HCl (240 mg) ranged from A$0.81 to A$3.04, and delivery costs from A$3.28 to
A$62.70.
Conclusion: Consumers who self-select medicines from websites have insufficient access to information
and advice at the point of ordering and on delivery to make informed decisions about their safe and
appropriate use.
The internet provides consumers with global access tohealth information, services and support. It has revolu-tionised the sale of medicines so that consumers can self-
select and buy medicines, often delivered across national and
state boundaries, without face to face interaction with a
health professional. e-Pharmacies are websites selling pre-
scription only medicines and other products including
non-prescription and complementary medicines.
To ensure the optimal use of medicines, consumers should
have timely access to quality information about their benefits,
risks, and appropriate usage.1 Consumers want information
about medicines but have different individual needs.2 3 Health
professionals who prescribe or dispense medicines have
professional, ethical, and legal responsibilities to provide con-
sumers with quality information and facilitate the safe and
appropriate use of medicines. Whether e-pharmacies provide
such information or advice is largely unknown.
Previous studies of e-pharmacies are limited to American
websites or those selling lifestyle medications, including
sildenafil and finasteride.4–10 Most studies regarding quality of
online information focus on specific diseases or treatments,
rather than the information and advice associated with the
delivery of pharmaceutical services.
As controversy brews over the announcement of a German
health insurance company that encourages consumers to buy
medicines via the internet,11 this study aims to examine
whether consumers can do so safely. It is the first study to
evaluate the quality of information published on global
e-pharmacy websites and to determine what happens when a
consumer orders a non-prescription or complementary medi-
cine from an e-pharmacy. In particular, we examined whether
staff exchanged information with, and provided relevant
advice to, consumers to promote the safe and appropriate use
of non-prescription and complementary medicines.
METHODS
In May 2001 e-pharmacy websites were identified using
Copernic (www.copernic.com), a metasearch engine that
simultaneously searches 10 global commercial search engines.
Search terms employed were “internet pharmacies”, “internet
pharmacy”, “internet medicines”, “online pharmacies”, “on-
line pharmacy”, and “online medicines”. Websites recording
multiple hits were included only once in the sampling frame.
Those that only offered electronic transfer of prescriptions
from doctor to pharmacy or prescription refills (increasingly
common in the USA), three members only sites, four sites
written in languages other than English, two sites with trans-
mission errors, and eight sites under development were
excluded.
Between July and September 2001 we surveyed all websites
in the sampling frame. The survey collected data in two
distinct sections—the quality of health information published
on e-pharmacies and a case study where medicines were pur-
chased via the internet.
The quality of health information was evaluated using the
DISCERN rating instrument which was specifically developed
and validated to assess a broad range of online and written
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consumer health information.12 DISCERN consists of 15 ques-
tions, each representing a unique quality criterion, plus an
overall quality rating.
The case study was undertaken by one of us (TB) acting as
a consumer who attempted to purchase one non-prescription
and one complementary medicine using a set case scenario
(box 1). Standardised patients are a useful method to assess
the quality of primary health care including pharmacy
practice.13–17 All products were to be delivered to a residential
address (not a post office box) in Melbourne, Australia.
We chose Sudafed (pseudoephedrine hydrochloride) and St
John’s wort (Hypericum perforatum) tablets for the case
scenario because they are both commonly used and widely
available. Pseudoephedrine HCl is often illegally misused to
manufacture amphetamines18–20 and in Australia its importa-
tion requires a licence from the Therapeutic Goods
Administration.21 St John’s wort products interact with many
medicines by altering drug metabolism or increasing central
nervous system serotonin levels.22 It can interact with
medicines including cyclosporin, digoxin, oral contraceptives,
theophylline, wafarin, anticonvulsants (carbamazepine, phe-
nobarbitone and phenytoin), selective serotonin reuptake
inhibitors (SSRIs) and related drugs (citalopram, fluoxetine,
paroxetine, sertraline, nefazodone), triptans (sumatriptan,
naratriptan, rizatriptan and zolmitriptan), human immuno-
deficiency virus (HIV) protease inhibitors, and HIV non-
nucleoside reverse transcriptase inhibitors.22 Serotonergic
syndrome is characterised by changes in mental status and
motor and autonomic function and is a potentially serious
adverse drug event that may occur when St John’s wort and
fluoxetine are taken concurrently.
Data on the nature of patient information collected by
pharmacy staff; the provision of written information and
advice by pharmacy staff; product recommendations; refer-
rals; payment security; delivery costs, times and methods;
customs inspections; and the condition of the product received
were collected. The information exchanged with and advice
provided to consumers by e-pharmacy staff was assessed
using pharmacy practice standards and current guidelines.23
We also assessed whether e-pharmacies had processes in place
to detect the potential drug interaction between St John’s wort
and fluoxetine. (A copy of the survey tool is available upon
request from the first author.)
The Monash University Standing Committee on Ethics in
Research Involving Humans gave ethics approval for this
study. Informed consent was not sought from e-pharmacy
operators before buying these medicines because of the simu-
lated nature of the project. However, in accordance with the
recommendations of the ethics committee, we sent
e-pharmacies that delivered medicines a hard copy of the data
collected from their individual website 1 month after delivery
and each had the opportunity to withdraw their results from
the study.
The data were summarised using descriptive statistics.
RESULTS
Quality of information
We identified and surveyed 104 unique e-pharmacy websites
from at least 13 different countries; 63 (61%) provided some
health information, 51 (49%) provided some information
about medicines, 31 (30%) published information on disease
states, 17 (16%) provided lifestyle information, 41 (40%) pro-
vided no information, and 53 (51%) published poor quality
information of limited or no benefit (table 1).
Of the 104 e-pharmacies, 52 (50%) allowed consumers to
search by trade name, 55 (53%) by therapeutic class, and 22
(21%) by therapeutic substance, while 35 (34%) offered no
search function at all. Thirty (29%) websites displayed
external links, most commonly to consumer health support
groups and online medical libraries, but others included one
online gambling site and two news websites.
Twenty five websites published information about pseu-
doephedrine HCl. Of these, 21 (84%) published useful
information (DISCERN rating 4 or 5) about the benefits asso-
ciated with taking pseudoephedrine HCl but only 13 (52%)
published such information about risks. Nineteen websites
published information about St John’s wort products and
overall the information about the benefits and risks of these
products was more balanced (17 and 18 websites, respec-
tively). However, the information was often of a general
nature and less useful. For example, “this medication may
interact with other medicines” rather than “this medicine
interacts with a list of specific therapeutic substances”.
Case study
Of the 104 e-pharmacies, 31 (30%) and 41 (40%) websites sold
pseudoephedrine HCl and St John’s wort, respectively. Fifteen
of the 31 (48%) delivered pseudoephedrine HCl (14 Sudafed
and one local generic product) while 26 of the 41 (63%) deliv-
ered various St John’s wort products to Australia. Fourteen
e-pharmacies delivered both products and a total of 27 pack-
ages were received from Australia, Canada, New Zealand, UK,
and the USA. Sixteen (52%) and 15 (37%) of the e-pharmacies
selling pseudoephedrine HCl and St John’s wort, respectively,
did not deliver these medicines to Australia, largely because 31
(30%) of the 104 e-pharmacies only deliver such medicines
within their national borders. No e-pharmacies withdrew
their results.
Of the 27 e-pharmacies that supplied medicines, 13 (48%)
required consumers to register a user name and password.
Twenty five websites (93%) confirmed the order and delivery
details of products via email. All sites used secure socket layer
(SSL) technology for payment transactions. The operation of
these e-pharmacies appeared to involve registered pharma-
cists and no websites sold prescription only medicines without
a prescription written by a doctor.
Of the 27 e-pharmacies that supplied medicines, 15 (56%)
provided information about directions for use, eight (30%)
about treatment length, 14 (52%) about potential adverse
events, 11 (41%) about interactions, and four (15%) offered
what to do if ther condition did not improve. No sites
suggested associated ancillary lifestyle changes, and no
e-pharmacy staff recommended alternative or additional
products. Upon delivery the only written information about
the medicines received was one manufacturer’s information
sheet regarding the use of pseudoephedrine HCl and one
information sheet regarding St John’s wort and potential drug
interactions.
Box 1: Case scenario (35 year old Australian woman)
Place an order for Sudafed (preferred brand) or
pseudoephedrine HCl (30–120 mg) (single therapeutic
ingredient), quantity 10–60 capsules/tablets and St John’s
wort 100 mg+, quantity 10–60 (no preferred brand) from
an online supplier of scheduled medicines. Choose the
cheapest Sudafed or St John’s wort product if multiple
options are available.
The Sudafed or pseudoephedrine HCl product is for
your own use. You have had a runny nose for a couple of
days and a friend suggested you try it; you have not used
this product before or tried anything else to treat the prob-
lem. The St John’s wort is also for your own use. You have
been feeling really flat and low and you read about St
John’s wort in a magazine; you have not used this product
before. You have taken Prozac (fluoxetine) for depression
for the past 3 months after being in a car accident. You are
not taking any other medications and have no other
illnesses.
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Of the 26 e-pharmacies that supplied St John’s wort
products, five (19%) websites asked for consumer information
that could have enabled staff to detect the potential drug
interaction involving fluoxetine and St John’s wort, but only
three (12%) contacted the consumer about this concern. The
three e-pharmacies initially communicated via email asking
for additional contact. Three e-pharmacists subsequently
counselled the consumer by telephone and correctly referred
the consumer to see her doctor before commencing self-
medication with St John’s wort. The staff of the remaining 21
(81%) e-pharmacies could not detect this potential drug
interaction because they failed to exchange relevant infor-
mation with consumers.
Products were received by post (12, 44%), registered post
(11, 41%), and courier (4, 15%) and signatures were required
on 15 (56%) occasions. Eight of 16 (50%) international deliv-
eries were opened, inspected, and resealed by Australian cus-
toms officers. Two packages (13%) containing pseudoephe-
drine HCl products had no tangible evidence of customs
inspection.Upon delivery,we identified the sender of 16 (60%)
packages by information visible on the exterior of the package,
19 (70%) by descriptions of package contents, and three (11%)
packages by deduction using postmarks and dates. Sixteen
(60%) were packed in boxes and 11 (40%) in envelopes.
Twenty two (81%) packages contained bubble wrap or similar
materials. Despite these packaging precautions, two (7%)
products were damaged at the time of delivery.
Specific errors included one delivery of an out of date St
John’s wort product (expired August 2001, delivered Septem-
ber 2001) and one package was sent to the billing address
instead of the residential address. The e-pharmacy that
supplied the out of date product was contacted by email and a
refund was offered. One pharmacy also substituted a different
brand of St John’s wort from that originally ordered with no
notification or explanation about the change.
The product costs, postage and handling charges, and deliv-
ery times were highly variable. For example, the product costs
of a total daily dose of pseudoephedrine HCl 240 mg ranged
from A$0.82 to A$3.04 (mean A$1.50, 95% CI 1.13 to 1.87).
Costs of St John’s wort products also varied but are not com-
parable because of inconsistent recommended daily dosages
and the non-standardised nature of some complementary
medicine products. Postage and handling charges ranged from
A$3.28 to A$62.70 (median A$7.54). The product, postage and
handling costs were most expensive for deliveries from the
USA. All costs are given in Australian dollars (A$) where
A$1=£0.37 and US$0.52. Delivery times ranged from 2 to 18
days (mean 6 (95% CI 4.5 to 7.5)).
DISCUSSION
Australian internet pharmacy practice standards state that
“the pharmacist provides medicines and devices through the
internet in a manner which safeguards the privacy and confi-
dentiality of the patient, delivers the correct product with
appropriate information to the patient, and promotes safe,
correct and appropriate use of medicines.”24 Despite the intro-
duction of similar standards and guidelines in Canada, New
Zealand, the UK and the USA,25–28 we found that most
e-pharmacies (including those operating in these countries)
selling non-prescription and complementary medicines failed
to uphold the intent of these standards. This study shows that
consumers who self-select non-prescription medicines from
e-pharmacies are at risk of medication misadventures.
Consumers cannot make an informed decision about
purchasing a medicine using information provided by
e-pharmacies because balanced information about the ben-
efits and risks of taking medicines was largely not available or
of poor quality. Furthermore, written information was rarely
provided upon delivery. Although the packaging contains
some information, it alone does not adequately protect
consumers from harm.29 Pharmacists have a duty of care to
ensure that consumers are provided with sufficient infor-
mation to assist the safe and effective use of medicines to
Table 1 Frequency of DISCERN ratings of health information given by e-pharmacies
by geographical location
Location Total no No
DISCERN rating*
1 2 3 4 5
Australasia
Australia 12 2 4 6
New Zealand 13 3 1 4 5
North America
Bermuda 1 1
Canada 4 2 1 1
Mexico 1 1
USA 40 14 1 9 7 4 5
Asia







UK 4 1 2 1
Unknown 22 14 1 6 1
Total 104 41 7 26 20 5 5
*DISCERN ratings: 5=high, indicates that the publication is of “good” quality (a useful and appropriate
source of information about treatment choices); 3=moderate, indicates that the publication is of “fair” quality
(a useful source of information about treatment choices but has some limitations; additional information or
support would definitely be needed); 1=low, indicates that the publication is of “poor” quality (has serious
shortcomings and is not a useful or appropriate source of information about treatment choices; it is unlikely to
be of any benefit and should not be used).
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optimise health outcomes.30 e-Pharmacy operators must be
encouraged to provide consumers with quality balanced phar-
maceutical information at the right place and time: infor-
mation linked to individual products at the point of ordering
and upon delivery.
Medical and consumer literature identifies the importance
of an exchange and sharing of information between consum-
ers and health professionals to achieve positive health
outcomes.31 In traditional “bricks and mortar” practices
consumers can be provided with, or ask for, advice about
medicines, and such advice is generally valued.32 Pharmacists
also refer consumers to their doctor when necessary. UK
research has shown that, in about a quarter of pharmacist-
consumer consultations, no sale is made and pharmacists
often recommend customers to see their doctor.33 In an online
environment the exchange of information between pharma-
cists and patients requires easy to use and secure electronic
communication processes. It is therefore disturbing that the
majority of e-pharmacy staff were unable to detect a
potentially serious drug interaction because processes were
not in place to obtain relevant information about consumers,
including their current medications.
One of the potential strengths of the internet is to provide
consumers with informed choices. Medicines have many
different trade names, and the same therapeutic substances
have different approved names in different countries—for
example, paracetamol (UK) and acetaminophen (USA). Con-
sumers wishing to compare brands, formulations, and prices
of similar products should be able to search by therapeutic
substance or class, but less than half the e-pharmacies
provided such a capability. e-Pharmacies could incorporate
these and other consumer friendly online features including
drug-drug and drug-disease interaction checks, self-
monitoring tools, and medication charts and diaries.
Despite cost being a major driver of online consumerism
and the relatively free trade of non-prescription medicines, we
observed large price disparities between medicines sold by
e-pharmacies operating in different countries. Consumers are
more likely to realise cost savings from e-pharmacies when
purchasing multiple items, and whether they consequently
buy more products than those immediately required is
unknown.
Ultimately, consumers will decide whether or not to
purchase medicines from e-pharmacies, as safeguarding the
privacy and confidentiality of the consumers is paramount to
its sustainability as a commercial resource. Although discrete
packaging protects consumers from potential embarrassment,
the origin of medicines sent via the postal system should be
identifiable by customs officers and consumers. All packages
should include contact details of the sender. Furthermore,
errors and the damaged condition of some products upon
delivery may deter consumers from repeated use of
e-pharmacies.
The results of this study are tempered by some method-
ological limitations. Although we searched broadly using a
rigorous identification strategy, it is difficult to determine
whether this sample of 104 websites was entirely representa-
tive because the total current number of e-pharmacies operat-
ing at any one time is unknown. Due to the nature of the
internet, it is difficult to evaluate whether an e-pharmacy is
bona fide unless the site displays a seal that can be electroni-
cally verified by an independent pharmacy statutory body.27
Furthermore, it is almost impossible to know with whom you
are dealing or the location or ownership of e-pharmacies. Of
the 27 that supplied medicines to us, all appeared to involve a
qualified pharmacist, but whether qualified or unqualified
staff supervised our medication order was unknown. Most
countries legally permit the export and import of non-
prescription medicines for personal use, but only approxi-
mately half of the e-pharmacies selling pseudoephedrine HCl
and St John’s wort products delivered such medicines to Aus-
tralia. The reasons for this are unknown, but limited the sam-
ple size of the case study. Despite these limitations, this study
provides a unique insight into e-pharmacy practice in 2001.
We conclude that internet technologies should be used to
develop ethical and innovative practice models that make the
management of medications for consumers easier, simpler,
and safer to achieve positive health outcomes, but surfing and
self-medicating is currently not safe. Consumer education
about the benefits and risks of buying medicines via the inter-
net is needed because national e-pharmacy standards alone
do not adequately address the overall lack of information and
advice provided. It is vital that such standards address the
needs for pharmacists and consumers to exchange infor-
mation and prevent self-medication misadventures. To sup-
port the safe and appropriate use of non-prescription and
complementary medicines, e-pharmacies must go beyond sat-
isfying minimum practice standards and deliver consumer
focused services including the provision of quality medicines
information linked to the product at the time of ordering, and
written information on the delivery of medicines.
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